At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 463 enrolled
Drug / intervention
FF/UMEC/VIdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week, Prospective, Open Label, Single Cohort Study to Evaluate the Real-world Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (Trelegy Ellipta) in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) Patients
In Brief
A Phase 4 clinical trial evaluating FF/UMEC/VI for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 463 participants across 1 site.
Detailed Summary
The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on health status in participants with symptomatic COPD. The secondary objective is to evaluate the effectiveness of TRELEGY ELLIPTA on dyspnea and lung function in participants with symptomatic COPD. TRELEGY and ELLIPTA are trademarks of the GlaxoSmithKline group of companies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartOct 2022
Primary CompletionSep 2023
TodayJul 2026
First PostedSep 10, 2022
Enrollment StartOct 14, 2022
Primary CompletionSep 25, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.8 years ago
Interventions
FF/UMEC/VIdrug
FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.